US6750329B1
(en)
*
|
1989-05-05 |
2004-06-15 |
Research Development Foundation |
Antibody delivery system for biological response modifiers
|
US6710174B2
(en)
*
|
2001-09-13 |
2004-03-23 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of vascular endothelial growth factor receptor-1 expression
|
DK0807183T3
(da)
*
|
1994-08-26 |
2001-03-05 |
Aventis Pharma Gmbh |
Genterapi af sygdomme, der fremkaldes af immunsystemet, ved hjælp af et cellespecifikt aktivt stof, der reguleres af cellec
|
GB9506466D0
(en)
|
1994-08-26 |
1995-05-17 |
Prolifix Ltd |
Cell cycle regulated repressor and dna element
|
US7087582B1
(en)
|
1995-09-26 |
2006-08-08 |
Regents Of The University Of Michigan |
Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21
|
GB9616685D0
(en)
*
|
1995-10-02 |
1996-09-25 |
Cancer Res Campaign Tech |
Antitumour vector constructs and methods
|
DE19605279A1
(de)
|
1996-02-13 |
1997-08-14 |
Hoechst Ag |
Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
|
AUPN816196A0
(en)
*
|
1996-02-19 |
1996-03-14 |
Forbio Research Pty Ltd |
Regulation of eukaryotic gene expression
|
DE19617851A1
(de)
*
|
1996-05-03 |
1997-11-13 |
Hoechst Ag |
Nukleinsäurekonstrukte mit Genen kodierend für Transportsignale
|
DE19639103A1
(de)
|
1996-09-24 |
1998-03-26 |
Hoechst Ag |
Nukleinsäurekonstrukte mit Hybridpromotoren für gentherapeutische Maßnahmen
|
DE19651443A1
(de)
|
1996-12-11 |
1998-06-18 |
Hoechst Ag |
Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme
|
DE19701141C1
(de)
|
1997-01-16 |
1998-04-09 |
Hoechst Ag |
Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
|
DE19704301C1
(de)
*
|
1997-02-06 |
1998-03-26 |
Hoechst Ag |
Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie
|
US6294170B1
(en)
|
1997-08-08 |
2001-09-25 |
Amgen Inc. |
Composition and method for treating inflammatory diseases
|
EP0860445A1
(en)
*
|
1997-02-18 |
1998-08-26 |
Hoechst Aktiengesellschaft |
New nucleotide sequences for the cell cycle regulated expression of structural genes
|
US7112338B2
(en)
*
|
1997-03-12 |
2006-09-26 |
The Regents Of The University Of California |
Cationic liposome delivery of taxanes to angiogenic blood vessels
|
US5837283A
(en)
*
|
1997-03-12 |
1998-11-17 |
The Regents Of The University Of California |
Cationic lipid compositions targeting angiogenic endothelial cells
|
DE19710643A1
(de)
*
|
1997-03-14 |
1998-09-17 |
Hoechst Ag |
Der Promotor des cdc25B Genes und seine Verwendung in der Gentherapie
|
US6696423B1
(en)
|
1997-08-29 |
2004-02-24 |
Biogen, Inc. |
Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
|
DE19751587A1
(de)
|
1997-11-21 |
1999-07-29 |
Hoechst Marion Roussel De Gmbh |
Onkogen- oder virusgesteuerte Expressionssysteme
|
GB9724829D0
(en)
*
|
1997-11-21 |
1998-01-21 |
Muller Rolf |
Transcription factor
|
DE19756975A1
(de)
|
1997-12-20 |
1999-06-24 |
Hoechst Marion Roussel De Gmbh |
Bindungspartner für Inhibitoren von cyclinabhängigen Kinasen und ihre Verwendung zur Suche nach Inhibitoren, zur Diagnose oder zur Therapie einer Erkrankung
|
CZ121599A3
(cs)
|
1998-04-09 |
1999-10-13 |
Aventis Pharma Deutschland Gmbh |
Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
|
NZ508120A
(en)
*
|
1998-04-17 |
2003-10-31 |
Rigel Pharmaceuticals Inc |
Multiparameter FACS assays to detect alterations in cellular parameters and to screen small molecule libraries
|
DE19831420A1
(de)
*
|
1998-07-14 |
2000-01-20 |
Hoechst Marion Roussel De Gmbh |
Expressionssysteme enthaltend chimäre Promotoren mit Bindungsstellen für rekombinante Transkriptionsfaktoren
|
AU5318299A
(en)
*
|
1998-07-27 |
2000-02-21 |
Valentis, Inc. |
Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same
|
DE69929074T2
(de)
*
|
1998-09-11 |
2006-08-10 |
Thomas Jefferson University |
Verwendung von einem rb2/p130 exprimierenden vektor zur verhinderung oder behandlung von restenose oder atherosklerotischen ablagerungen
|
US6649158B1
(en)
*
|
1998-10-15 |
2003-11-18 |
Canji, Inc. |
Methods and compositions to induce antitumor response
|
US6867203B2
(en)
|
1998-12-29 |
2005-03-15 |
Abbott Laboratories |
Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
|
US6903077B1
(en)
|
1999-01-04 |
2005-06-07 |
University Of Vermont And State Agricultural College |
Methods and products for delivering nucleic acids
|
US6780986B1
(en)
|
1999-01-04 |
2004-08-24 |
University Of Vermont And State Agricultural College |
RIP60 nucleic acid and polypeptide sequences and uses therefor
|
DE19900743A1
(de)
|
1999-01-12 |
2000-07-13 |
Aventis Pharma Gmbh |
Neue komplexbildende Proteine
|
US6222096B1
(en)
*
|
1999-03-01 |
2001-04-24 |
Stine Biotechnology |
Promoter and construct for plant transformation
|
AU3755800A
(en)
*
|
1999-03-15 |
2000-10-04 |
Introgen Therapeutics, Inc. |
Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
|
KR100674140B1
(ko)
*
|
1999-03-23 |
2007-01-26 |
다카라 바이오 가부시키가이샤 |
유전자 치료제
|
EP1754488A1
(en)
|
1999-05-24 |
2007-02-21 |
Introgen Therapeutics, Inc. |
Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
|
UA74146C2
(uk)
*
|
1999-06-08 |
2005-11-15 |
Редженерон Фармасьютікалс, Інк. |
Модифікований хімеричний поліпептид з покращеними фармакокінетичними властивостями
|
JP4848113B2
(ja)
*
|
1999-09-09 |
2011-12-28 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
血管新生血管に対するタキサンの陽イオン性リポソーム送達
|
EP1225922A4
(en)
*
|
1999-11-03 |
2005-07-20 |
Medigene Oncology Gmbh |
EXPRESSION OF SELECTIVE TOXIN IN ENGINEERING ENDOTHELIAL CELLS
|
WO2001049868A1
(en)
*
|
1999-12-31 |
2001-07-12 |
Korea Research Institute Of Bioscience And Biotechnology |
Cancer cell-specific gene expression system
|
US7361643B2
(en)
|
2000-02-09 |
2008-04-22 |
University Of Puerto Rico |
Methods for inhibiting angiogenesis
|
AU2001262216A1
(en)
*
|
2000-04-22 |
2001-11-07 |
Stefan Barth |
Apoptotic agents
|
US10293056B1
(en)
|
2000-05-24 |
2019-05-21 |
Board Of Regents, The University Of Texas System |
Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
|
WO2002004953A2
(en)
|
2000-07-12 |
2002-01-17 |
Agensys, Inc. |
Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers
|
KR100488341B1
(ko)
*
|
2000-07-31 |
2005-05-11 |
주식회사 삼양제넥스 |
피972 유전자를 포함하는 유전자 전달체, 피972 유전자를 세포내에서 생산할 수 있는 아데노바이러스
|
US8039261B2
(en)
*
|
2000-11-17 |
2011-10-18 |
Vascular Biogenics Ltd. |
Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
|
US20070286845A1
(en)
*
|
2000-11-17 |
2007-12-13 |
Vascular Biogenics Ltd. |
Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
|
US20100282634A1
(en)
*
|
2000-11-17 |
2010-11-11 |
Dror Harats |
Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
|
AU2003222427B8
(en)
|
2000-11-17 |
2010-04-29 |
Vascular Biogenics Ltd. |
Promoters exhibiting endothelial cell specificity and methods of using same
|
US8071740B2
(en)
|
2000-11-17 |
2011-12-06 |
Vascular Biogenics Ltd. |
Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
|
US6838452B2
(en)
|
2000-11-24 |
2005-01-04 |
Vascular Biogenics Ltd. |
Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
|
CN1183250C
(zh)
*
|
2000-12-01 |
2005-01-05 |
卫健生物科技有限公司 |
高效表达肿瘤血管生成抑制因子的肿瘤细胞内特异性增殖的病毒及其构建方法
|
CA2429769C
(en)
*
|
2000-12-07 |
2016-04-26 |
Board Of Regents, The University Of Texas System |
Methods of treatment involving human mda-7
|
ZA200305980B
(en)
*
|
2001-02-12 |
2007-01-31 |
Res Dev Foundation |
Modified proteins, designer toxins, and methods of making thereof
|
CA2441434A1
(en)
*
|
2001-03-12 |
2002-09-19 |
Institute Of Gene And Brain Science |
Remedies for nerve damages
|
US20030003074A1
(en)
*
|
2001-06-14 |
2003-01-02 |
Macromed, Inc. |
Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
|
US20060159657A1
(en)
*
|
2001-06-14 |
2006-07-20 |
Macromed, Incorporated |
Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
|
JP2004535202A
(ja)
|
2001-07-17 |
2004-11-25 |
リサーチ ディベロップメント ファンデーション |
アポトーシス促進性蛋白質を含む治療剤
|
EP2131198B1
(en)
|
2001-09-20 |
2013-03-27 |
Board of Regents, The University of Texas System |
Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
|
US6734017B2
(en)
|
2001-09-28 |
2004-05-11 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of vascular endothelial growth factor receptor-2 expression
|
EP2277887A3
(en)
*
|
2001-10-19 |
2011-02-16 |
Vascular Biogenics Ltd. |
Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
|
AU2002360610A1
(en)
*
|
2001-12-12 |
2003-07-09 |
Children's Hospital Of Orange County |
A novel regulatory element within the il-ialpha promoter and uses thereof
|
US20040009939A1
(en)
*
|
2002-03-05 |
2004-01-15 |
Board Of Regent, The University Of Texas System |
Methods of enhancing immune induction involving MDA-7
|
US20040121955A1
(en)
*
|
2002-04-01 |
2004-06-24 |
Mulligan-Kehoe Mary Jo |
Methods for modulating angiogenesis
|
JP2006506964A
(ja)
*
|
2002-06-12 |
2006-03-02 |
リサーチ ディベロップメント ファンデーション |
治療剤としての免疫毒素及びその利用
|
EP2269619A1
(en)
|
2002-08-12 |
2011-01-05 |
Jennerex Biotherapeutics ULC |
Methods and compositions concerning poxviruses and cancer
|
JP2006506975A
(ja)
*
|
2002-08-19 |
2006-03-02 |
イェン、ユン |
肝疾患の治療
|
US7208493B2
(en)
*
|
2002-10-03 |
2007-04-24 |
Targegen, Inc. |
Vasculostatic agents and methods of use thereof
|
US20050282814A1
(en)
*
|
2002-10-03 |
2005-12-22 |
Targegen, Inc. |
Vasculostatic agents and methods of use thereof
|
CA2518150C
(en)
*
|
2003-03-03 |
2015-08-11 |
Board Of Regents, The University Of Texas System |
Methods and compositions involving mda-7
|
AU2004285477A1
(en)
|
2003-10-22 |
2005-05-12 |
Fred Hutchinson Cancer Research Center |
Methods, compositions and devices for inducing stasis in tissues and organs
|
US8034790B2
(en)
*
|
2003-12-01 |
2011-10-11 |
Introgen Therapeutics |
Use of MDA-7 to inhibit pathogenic infectious organisms
|
US20070281041A1
(en)
*
|
2004-03-02 |
2007-12-06 |
Introgen Therapeutics, Inc. |
Compositions and Methods Involving MDA-7 for the Treatment of Cancer
|
WO2005085455A1
(en)
*
|
2004-03-09 |
2005-09-15 |
Kam Man Hui |
Compositions and methods for treating disease
|
CA2567574C
(en)
*
|
2004-04-08 |
2013-01-08 |
Targegen, Inc. |
Benzotriazine inhibitors of kinases
|
EP2471924A1
(en)
|
2004-05-28 |
2012-07-04 |
Asuragen, INC. |
Methods and compositions involving microRNA
|
NZ553492A
(en)
|
2004-08-25 |
2010-11-26 |
Targegen Inc |
Triazole derivatives and methods of use
|
US7566701B2
(en)
|
2004-09-07 |
2009-07-28 |
Archemix Corp. |
Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
|
WO2006029258A2
(en)
*
|
2004-09-07 |
2006-03-16 |
Archemix Corp. |
Aptamer medicinal chemistry
|
CA2579374A1
(en)
|
2004-09-07 |
2006-03-30 |
Archemix Corp. |
Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
|
EP2302055B1
(en)
|
2004-11-12 |
2014-08-27 |
Asuragen, Inc. |
Methods and compositions involving miRNA and miRNA inhibitor molecules
|
CA2597329C
(en)
*
|
2005-02-08 |
2016-10-11 |
Board Of Regents, The University Of Texas System |
Compositions and methods involving mda-7 for the treatment of cancer
|
AU2006236150A1
(en)
*
|
2005-04-20 |
2006-10-26 |
Fred Hutchinson Cancer Research Center |
Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
|
WO2006124700A2
(en)
*
|
2005-05-12 |
2006-11-23 |
Introgen Therapeutics, Inc. |
P53 vaccines for the treatment of cancers
|
EP1893216A4
(en)
*
|
2005-06-08 |
2012-08-08 |
Targegen Inc |
METHOD AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
CA2621982C
(en)
*
|
2005-09-07 |
2017-11-28 |
Jennerex Biotherapeutics Ulc |
Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
|
US8133900B2
(en)
*
|
2005-11-01 |
2012-03-13 |
Targegen, Inc. |
Use of bi-aryl meta-pyrimidine inhibitors of kinases
|
US8604042B2
(en)
*
|
2005-11-01 |
2013-12-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
PT1951684T
(pt)
*
|
2005-11-01 |
2016-10-13 |
Targegen Inc |
Inibidores de cinases de tipo biaril-meta-pirimidina
|
US20090074733A1
(en)
*
|
2005-12-09 |
2009-03-19 |
Medin Jeffrey A |
Thymidylate kinase mutants and uses thereof
|
US20090068158A1
(en)
*
|
2005-12-09 |
2009-03-12 |
Medin Jeffrey A |
Thymidylate kinase mutants and uses thereof
|
WO2007092944A2
(en)
*
|
2006-02-08 |
2007-08-16 |
Introgen Therapeutics, Inc. |
Compositions and methods involving gene therapy and proteasome modulation
|
EP2495327B1
(en)
|
2006-03-03 |
2016-09-28 |
ProMIS Neurosciences Inc. |
Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
|
US7691858B2
(en)
*
|
2006-04-25 |
2010-04-06 |
Targegen, Inc. |
Kinase inhibitors and methods of use thereof
|
CN102026645B
(zh)
|
2006-09-15 |
2016-01-27 |
渥太华医院研究机构 |
溶瘤弹状病毒
|
AU2007299748A1
(en)
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
miR-15, miR-26, miR -31,miR -145, miR-147, miR-188, miR-215, miR-216 miR-331, mmu-miR-292-3p regulated genes and pathways as targets for therapeutic intervention
|
US20080131878A1
(en)
*
|
2006-12-05 |
2008-06-05 |
Asuragen, Inc. |
Compositions and Methods for the Detection of Small RNA
|
AU2007333106A1
(en)
*
|
2006-12-08 |
2008-06-19 |
Asuragen, Inc. |
miR-20 regulated genes and pathways as targets for therapeutic intervention
|
KR20080084528A
(ko)
*
|
2007-03-15 |
2008-09-19 |
제네렉스 바이오테라퓨틱스 인크. |
종양살상형 백시니아 바이러스 암 치료
|
CA2584494A1
(en)
*
|
2007-03-27 |
2008-09-27 |
Jeffrey A. Medin |
Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
|
AR060702A1
(es)
|
2007-04-27 |
2008-07-10 |
Fundacion Inst Leloir |
Promotor inducible por especies reactivas del oxigeno y vector que lo comprende
|
US8765462B2
(en)
|
2007-05-04 |
2014-07-01 |
University Health Network |
IL-12 immunotherapy for cancer
|
WO2008150495A2
(en)
*
|
2007-06-01 |
2008-12-11 |
Archemix Corp. |
Vwf aptamer formulations and methods for use
|
EP2198050A1
(en)
|
2007-09-14 |
2010-06-23 |
Asuragen, INC. |
Micrornas differentially expressed in cervical cancer and uses thereof
|
WO2009070805A2
(en)
|
2007-12-01 |
2009-06-04 |
Asuragen, Inc. |
Mir-124 regulated genes and pathways as targets for therapeutic intervention
|
WO2009114942A1
(en)
|
2008-03-20 |
2009-09-24 |
University Health Network |
Thymidylate kinase fusions and uses thereof
|
US8258111B2
(en)
|
2008-05-08 |
2012-09-04 |
The Johns Hopkins University |
Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
|
CA2750922A1
(en)
*
|
2009-01-28 |
2010-08-05 |
Antigen Express, Inc. |
Li-key hybrid peptides that modulate the immune response to influenza
|
US20110045080A1
(en)
*
|
2009-03-24 |
2011-02-24 |
William Marsh Rice University |
Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto
|
ES2848650T3
(es)
|
2009-09-14 |
2021-08-11 |
Sillajen Biotherapeutics Inc |
Terapia combinada contra el cáncer con virus vaccinia oncolítico
|
AU2010329551B2
(en)
|
2009-12-10 |
2016-02-11 |
Turnstone Limited Partnership |
Oncolytic rhabdovirus
|
AU2011212885B2
(en)
|
2010-02-04 |
2015-10-01 |
Aemase, Inc. |
Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof
|
WO2011107100A1
(en)
|
2010-03-03 |
2011-09-09 |
Aarhus Universitet |
Methods and compositions for regulation of herv4
|
US9309534B2
(en)
|
2010-07-12 |
2016-04-12 |
Universidad Autonoma De Barcelona |
Gene therapy composition for use in diabetes treatment
|
AU2010363329A1
(en)
|
2010-11-07 |
2013-05-09 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
CN103429258B
(zh)
|
2011-01-04 |
2016-03-09 |
新罗杰公司 |
通过施用溶瘤痘苗病毒生成针对肿瘤抗原的抗体和生成肿瘤特异性补体依赖性细胞毒性
|
JP2014506791A
(ja)
|
2011-02-03 |
2014-03-20 |
マーナ セラピューティクス インコーポレイテッド |
miR−34の合成模倣体
|
WO2012106586A1
(en)
|
2011-02-03 |
2012-08-09 |
Mirna Therapeutics, Inc. |
Synthetic mimics of mir-124
|
WO2012167382A1
(en)
|
2011-06-08 |
2012-12-13 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Compositions and methods for glioblastoma treatment
|
AU2012294814A1
(en)
|
2011-08-05 |
2014-02-27 |
Research Development Foundation |
Improved methods and compositions for modulation of Olfml3 mediated angiogenesis
|
WO2013040251A2
(en)
|
2011-09-13 |
2013-03-21 |
Asurgen, Inc. |
Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
|
KR101421534B1
(ko)
|
2012-05-04 |
2014-07-24 |
전북대학교산학협력단 |
항균 활성 및 항암 활성이 강화된 리소좀의 제조방법
|
US20150283233A1
(en)
|
2012-06-15 |
2015-10-08 |
Gencia Corporation |
Compositions and Methods for Enhancing Immune Responses
|
UA114108C2
(uk)
|
2012-07-10 |
2017-04-25 |
Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем |
Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
|
EP2692868A1
(en)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
|
DK2912064T3
(da)
|
2012-10-24 |
2019-07-22 |
Res Found Dev |
Jam-c-antistoffer og fremgangsmåder til behandling af cancer
|
CN105051204B
(zh)
|
2012-11-16 |
2023-07-21 |
波赛伊达治疗学股份有限公司 |
位点特异性酶和使用方法
|
RU2684211C2
(ru)
|
2013-02-21 |
2019-04-04 |
Тёрнстоун Лимитед Партнершип |
Композиция вакцины
|
CA2921401A1
(en)
|
2013-08-14 |
2015-02-19 |
William Marsh Rice University |
Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
|
EP3036005A4
(en)
|
2013-08-21 |
2017-04-26 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for targeting connexin hemichannels
|
EP3039137B1
(en)
|
2013-08-29 |
2019-07-31 |
Board of Regents, The University of Texas System |
Engineered primate cystine/cysteine degrading enzymes as antineogenic agents
|
CA2922550C
(en)
|
2013-08-29 |
2022-12-06 |
Board Of Regents, The University Of Texas System |
Engineered primate l-methioninase for therapeutic purposes
|
CN105722522B
(zh)
|
2013-08-30 |
2021-10-19 |
得克萨斯大学体系董事会 |
用于肿瘤疗法的犬尿氨酸耗竭酶的施用
|
SI3076949T1
(sl)
|
2013-12-04 |
2020-01-31 |
Board Of Regents, The University Of Texas System |
Postopek za izoliranje eksosomov, ki izvirajo iz rakavih celic
|
RU2699539C2
(ru)
|
2013-12-23 |
2019-09-06 |
Арланксео Сингапур Пте. Лтд. |
Особочистые галогенированные каучуки
|
RU2716487C2
(ru)
*
|
2013-12-23 |
2020-03-13 |
Арланксео Сингапур Пте. Лтд. |
Новые противоагломераты для резиновой промышленности
|
US10647842B2
(en)
|
2013-12-23 |
2020-05-12 |
Arlanxeo Singapore Pte. Ltd. |
Anti-agglomerants for elastomeric ethylene/A-olefin copolymers
|
JP7080053B2
(ja)
|
2014-08-29 |
2022-06-03 |
ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与
|
WO2016033105A1
(en)
|
2014-08-29 |
2016-03-03 |
The Board Of Regents Of The University Of Texas System |
Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
|
WO2016110518A1
(en)
|
2015-01-07 |
2016-07-14 |
Universitat Autònoma De Barcelona |
Single-vector gene construct comprising insulin and glucokinase genes
|
JP6724023B2
(ja)
|
2015-02-09 |
2020-07-15 |
リサーチ ディベロップメント ファウンデーション |
改善された補体活性化を示す操作された免疫グロブリンfcポリペプチド
|
AU2016226133B2
(en)
|
2015-03-04 |
2021-12-02 |
Board Of Regents, The University Of Texas System |
Methods of treating cancer harboring hemizygous loss of TP53
|
JP2018520125A
(ja)
|
2015-06-10 |
2018-07-26 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
疾患の処置のためのエキソソームの使用
|
US11473082B2
(en)
|
2015-06-17 |
2022-10-18 |
Poseida Therapeutics, Inc. |
Compositions and methods for directing proteins to specific loci in the genome
|
WO2017019829A1
(en)
|
2015-07-28 |
2017-02-02 |
Board Of Regents, The University Of Texas System |
Implant compositions for the unidirectional delivery of therapeutic compounds to the brain
|
WO2017040380A2
(en)
|
2015-08-28 |
2017-03-09 |
Research Development Foundation |
Engineered antibody fc variants
|
US9744187B2
(en)
|
2015-10-14 |
2017-08-29 |
Bio-Path Holdings, Inc. |
p-Ethoxy nucleic acids for liposomal formulation
|
WO2017079746A2
(en)
|
2015-11-07 |
2017-05-11 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
|
CA3004438A1
(en)
|
2015-11-09 |
2017-05-18 |
The Children's Hospital Of Philadelphia |
Glypican 2 as a cancer marker and therapeutic target
|
EP3383908A1
(en)
|
2015-12-02 |
2018-10-10 |
Stsciences, Inc. |
Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
|
EP3909983A1
(en)
|
2015-12-02 |
2021-11-17 |
STCube & Co. Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
US10889637B2
(en)
|
2016-02-26 |
2021-01-12 |
The Board Of Regents Of The University Of Texas System |
Methods of treating an osteolytic tumor and spinal cord injury by administering connexin (Cx) 43 hemichannel-binding antibodies
|
JP2019511483A
(ja)
|
2016-03-02 |
2019-04-25 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
免疫療法のためのsting活性化ナノワクチン
|
WO2017172517A1
(en)
|
2016-03-29 |
2017-10-05 |
Stcube & Co., Inc. |
Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
|
US11660352B2
(en)
|
2016-03-29 |
2023-05-30 |
Stcube, Inc. |
Dual function antibodies specific to glycosylated PD-L1 and methods of use thereof
|
JP7131773B2
(ja)
|
2016-04-29 |
2022-09-06 |
ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
ホルモン受容体に関連する転写活性の標的尺度
|
CA3028771A1
(en)
|
2016-07-06 |
2018-01-11 |
Board Of Regents, The University Of Texas System |
Human-enzyme mediated depletion of cystine for treating patients with cystinuria
|
KR20190031299A
(ko)
|
2016-07-20 |
2019-03-25 |
주식회사 에스티큐브 |
글리코실화된 pd-l1에 결합하는 항체의 조합을 사용하는 암 치료 방법
|
WO2018035429A1
(en)
|
2016-08-18 |
2018-02-22 |
Wisconsin Alumni Research Foundation |
Peptides that inhibit syndecan-1 activation of vla-4 and igf-1r
|
MX2019003070A
(es)
|
2016-09-16 |
2019-10-14 |
Bio Path Holdings Inc |
Terapia de combinacion con oligonucleotidos antisentido liposomales.
|
US10316037B1
(en)
|
2016-11-04 |
2019-06-11 |
Yale University |
Compounds and methods for treating cancer
|
CA3043356A1
(en)
|
2016-11-09 |
2018-05-17 |
Musc Foundation For Research Development |
Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
|
WO2018111902A1
(en)
|
2016-12-12 |
2018-06-21 |
Multivir Inc. |
Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
|
WO2018156973A1
(en)
|
2017-02-24 |
2018-08-30 |
Board Of Regents, The University Of Texas System |
Assay for detection of early stage pancreatic cancer
|
CN107034215B
(zh)
*
|
2017-03-29 |
2019-12-13 |
华中科技大学同济医学院附属协和医院 |
一种cux1蛋白可结合dna片段及在cux1活性检测中的应用
|
MX2019013458A
(es)
|
2017-05-12 |
2020-01-15 |
Univ Texas |
Disminucion de homocisteina mediada por enzimas humanas para el tratamiento de pacientes con hiperhomocisteinemia y homocistinuria.
|
WO2018209211A1
(en)
|
2017-05-12 |
2018-11-15 |
Board Of Regents, The University Of Texas System |
Engineered primate cystine/cysteine degrading enzymes for therapeutic uses
|
JP7369038B2
(ja)
|
2017-05-31 |
2023-10-25 |
ストキューブ アンド シーオー., インコーポレイテッド |
Btn1a1に免疫特異的に結合する抗体及び分子並びにその治療的使用
|
JP2020522512A
(ja)
|
2017-05-31 |
2020-07-30 |
ストキューブ アンド シーオー., インコーポレイテッド |
Btn1a1に免疫特異的に結合する抗体及び分子を用いて癌を治療する方法
|
JP2020522562A
(ja)
|
2017-06-06 |
2020-07-30 |
ストキューブ アンド シーオー., インコーポレイテッド |
Btn1a1又はbtn1a1リガンドに結合する抗体及び分子を用いて癌を治療する方法
|
US11525002B2
(en)
|
2017-10-11 |
2022-12-13 |
Board Of Regents, The University Of Texas System |
Human PD-L1 antibodies and methods of use therefor
|
WO2019126578A1
(en)
|
2017-12-20 |
2019-06-27 |
Poseida Therapeutics, Inc. |
Compositions and methods for directing proteins to specific loci in the genome
|
EP3768698A4
(en)
|
2018-03-19 |
2022-03-30 |
MultiVir Inc. |
METHODS AND COMPOSITIONS COMPRISING TUMOR SUPPRESSIVE GENE THERAPY AND CD122/CD132 AGONISTS FOR THE TREATMENT OF CANCER
|
WO2019182896A1
(en)
|
2018-03-23 |
2019-09-26 |
Board Of Regents, The University Of Texas System |
Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
|
EP3773551A4
(en)
|
2018-03-27 |
2022-03-23 |
Board of Regents, The University of Texas System |
COMPOUNDS WITH ANTITUMOR ACTIVITY AGAINST CANCER CELLS CARRYING HER2 EXON 19 MUTATIONS
|
US20220033848A1
(en)
|
2018-11-19 |
2022-02-03 |
Board Of Regents, The University Of Texas System |
A modular, polycistronic vector for car and tcr transduction
|
WO2020113029A2
(en)
|
2018-11-28 |
2020-06-04 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
BR112021010248A2
(pt)
|
2018-11-29 |
2021-08-17 |
Board Of Regents, The University Of Texas System |
métodos para expansão ex vivo de células naturais killer e uso dos mesmos
|
JP2022519718A
(ja)
|
2019-02-08 |
2022-03-24 |
ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
加齢および加齢性臓器不全に関連する疾患の処置のためのテロメラーゼ含有エキソソーム
|
CA3138348A1
(en)
|
2019-05-09 |
2020-11-12 |
FUJIFILM Cellular Dynamics, Inc. |
Methods for the production of hepatocytes
|
TW202110431A
(zh)
|
2019-05-17 |
2021-03-16 |
美商癌症預防製藥股份有限公司 |
治療家族性腺瘤性瘜肉症之方法
|
JP2022541538A
(ja)
|
2019-07-19 |
2022-09-26 |
ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア |
グリピカン2結合ドメインを含有するキメラ抗原受容体
|
WO2021050953A1
(en)
|
2019-09-13 |
2021-03-18 |
Elektrofi, Inc. |
Compositions and methods for the delivery of therapeutic biologics for treatment of disease
|
CN114729045A
(zh)
|
2019-09-26 |
2022-07-08 |
斯特库比公司 |
对糖基化的ctla-4特异性的抗体及其使用方法
|
EP4041768A1
(en)
|
2019-10-09 |
2022-08-17 |
StCube & Co. |
Antibodies specific to glycosylated lag3 and methods of use thereof
|
US20220380765A1
(en)
|
2019-11-02 |
2022-12-01 |
Board Of Regents, The University Of Texas System |
Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
KR20220124718A
(ko)
|
2020-01-07 |
2022-09-14 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
암 치료를 위한 개선된 인간 메틸 티오아데노신/아데노신 고갈 효소 변이체
|
EP4107173A1
(en)
|
2020-02-17 |
2022-12-28 |
Board of Regents, The University of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
EP4153301A2
(en)
|
2020-05-21 |
2023-03-29 |
Board of Regents, The University of Texas System |
T cell receptors with vgll1 specificity and uses thereof
|
WO2021247836A1
(en)
|
2020-06-03 |
2021-12-09 |
Board Of Regents, The University Of Texas System |
Methods for targeting shp-2 to overcome resistance
|
EP4172370A1
(en)
|
2020-06-30 |
2023-05-03 |
Lunglife Ai, Inc. |
Methods for detecting lung cancer
|
WO2022104109A1
(en)
|
2020-11-13 |
2022-05-19 |
Catamaran Bio, Inc. |
Genetically modified natural killer cells and methods of use thereof
|
US20220162288A1
(en)
|
2020-11-25 |
2022-05-26 |
Catamaran Bio, Inc. |
Cellular therapeutics engineered with signal modulators and methods of use thereof
|
CN117529338A
(zh)
|
2021-01-19 |
2024-02-06 |
威廉马歇莱思大学 |
多肽的骨特异性递送
|
GB2603166A
(en)
|
2021-01-29 |
2022-08-03 |
Thelper As |
Therapeutic and Diagnostic Agents and Uses Thereof
|
IL310550A
(en)
|
2021-08-04 |
2024-03-01 |
Univ Colorado Regents |
LAT-activating chimeric antigen receptor T cells and methods of using them
|
CA3234457A1
(en)
|
2021-10-05 |
2023-04-13 |
Cytovia Therapeutics, Llc |
Natural killer cells and methods of use thereof
|
WO2023068382A2
(en)
|
2021-10-20 |
2023-04-27 |
Takeda Pharmaceutical Company Limited |
Compositions targeting bcma and methods of use thereof
|
WO2023076880A1
(en)
|
2021-10-25 |
2023-05-04 |
Board Of Regents, The University Of Texas System |
Foxo1-targeted therapy for the treatment of cancer
|
GB202201137D0
(en)
|
2022-01-28 |
2022-03-16 |
Thelper As |
Therapeutic and diagnostic agents and uses thereof
|
WO2023172514A1
(en)
|
2022-03-07 |
2023-09-14 |
Catamaran Bio, Inc. |
Engineered immune cell therapeutics targeted to her2 and methods of use thereof
|
WO2023192976A1
(en)
|
2022-04-01 |
2023-10-05 |
Board Of Regents, The University Of Texas System |
Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
|
WO2023211972A1
(en)
|
2022-04-28 |
2023-11-02 |
Medical University Of South Carolina |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|
WO2023220083A1
(en)
|
2022-05-09 |
2023-11-16 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
WO2023230531A1
(en)
|
2022-05-24 |
2023-11-30 |
Lunglife Ai, Inc. |
Methods for detecting circulating genetically abnormal cells
|
US20240010742A1
(en)
|
2022-06-10 |
2024-01-11 |
Research Development Foundation |
Engineered fcriib selective igg1 fc variants and uses thereof
|